Avoid common mistakes on your manuscript.
Correction: Ophthalmol Ther (2023) 12:2005–2021 https://doi.org/10.1007/s40123-023-00715-y
In the sentence beginning ‘When TAE regimens were compared, RBZ BS was dominant…’ of the Results section in the Abstract, the text ‘RBZ BS was dominant (higher quality-adjusted life-years (QALYs) and lower total cost) to AFL TAE and AFL to RBZ TAE’ should have read ‘RBZ BS was dominant (higher quality-adjusted life-years (QALYs) and lower total cost) to AFL TAE and AFL to RBZ BS TAE’.
In the sentence beginning ‘The top three influential parameters for RBZ BS TAE versus AFL TAE were…’ of the Deterministic Sensitivity Analysis section in Results, the text ‘(3) treatment frequency of AFL TAE in year 2 (lower to favorable for RBZ BS TAE)’ should have read ‘(3) treatment frequency of AFL TAE in year 2 (higher to favorable for RBZ BS TAE)’.
In the sentence beginning ‘Fourth, since the productivity loss of caregivers…’ under the Discussion, the text ‘with daily care related to the severity of visual impairment was available in existing studies and relied on expert opinions,…’ should have read ‘with daily care related to the severity of visual impairment was not available in existing studies and relied on expert opinions,…’.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Yanagi, Y., Takahashi, K., Iida, T. et al. Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan. Ophthalmol Ther 12, 2821–2822 (2023). https://doi.org/10.1007/s40123-023-00788-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40123-023-00788-9